In the context of genetic testing in a woman with breast or ovarian cancer in which a mosaic BRCA1/BRCA2 pathogenic variant is found, it currently remains appropriate to discuss risk management options as for constitutional carriers. This evidence concerns the gene BRCA2 and ovarian cancer.